Ectoine lozenges in the treatment of acute viral pharyngitis: a prospective, active-controlled clinical study.
Acute Disease
Administration, Oral
Adult
Aged
Amino Acids, Diamino
/ therapeutic use
Cough
/ drug therapy
Deglutition
Double-Blind Method
Female
Hoarseness
/ drug therapy
Humans
Hyaluronic Acid
/ therapeutic use
Male
Middle Aged
Pain
/ drug therapy
Pain Measurement
Patient Compliance
Pharyngitis
/ complications
Prospective Studies
Saline Solution, Hypertonic
/ therapeutic use
Treatment Outcome
Acute pharyngitis
Ectoine
Ectoine lozenges
Sore throat
Journal
European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
ISSN: 1434-4726
Titre abrégé: Eur Arch Otorhinolaryngol
Pays: Germany
ID NLM: 9002937
Informations de publication
Date de publication:
Mar 2019
Mar 2019
Historique:
received:
19
12
2018
accepted:
30
01
2019
pubmed:
11
2
2019
medline:
26
4
2019
entrez:
11
2
2019
Statut:
ppublish
Résumé
Acute pharyngitis is an uncomfortable disorder mostly caused by viruses and for which antibiotics are unwarranted. This study compared lozenges containing ectoine, a natural extremolyte, with hyaluronic acid lozenges and hypertonic saline gargle for symptomatic treatment of acute viral pharyngitis. This prospective, controlled clinical study, recruited 90 patients with moderate-to-severe pharyngitis symptoms who chose to use either ectoine (n = 35), hyaluronic acid (n = 35), or saline gargle (n = 20). Patients applied their 7-day treatment from the inclusion visit (V1) until the end-of-study visit (V2). Patients' pharyngitis symptoms, general health, general treatment effectiveness and tolerability, and patient compliance were assessed by investigators and patients. The sum score for three primary symptoms (pain on swallowing, urge to cough, and hoarseness) decreased by 79.5% (ectoine), 72.2% (hyaluronic acid), and 44.8% (saline gargle). Both lozenges were significantly superior to saline gargle (P < 0.05). Regarding general health improvement, ectoine was significantly superior to saline gargle (72.5% vs. 45.2%, P < 0.05), but hyaluronic acid (63.3%) was not. At V2, 65.7% of patients receiving ectoine reported "very good" general health vs. 48.6% of those receiving hyaluronic acid and 20.0% using saline gargle. Ectoine was significantly superior (P < 0.05) to both hyaluronic acid and saline gargle in terms of tolerability and patient compliance. No patients taking ectoine reported unpleasant sensations while applying their treatment, whereas almost half of patients using hyaluronic acid lozenges and saline gargle did. Treatment with ectoine lozenges significantly relieves moderate-to-severe symptoms of acute viral pharyngitis and is more effective and tolerable than treatments with hyaluronic acid lozenges and hypertonic saline gargle.
Identifiants
pubmed: 30739176
doi: 10.1007/s00405-019-05324-9
pii: 10.1007/s00405-019-05324-9
pmc: PMC6411829
doi:
Substances chimiques
Amino Acids, Diamino
0
Saline Solution, Hypertonic
0
ectoine
7GXZ3858RY
Hyaluronic Acid
9004-61-9
Types de publication
Controlled Clinical Trial
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
775-783Subventions
Organisme : bitop AG
ID : Not applicable
Références
Int J Clin Pract. 2017 Sep;71(9):
pubmed: 28869722
J Allergy (Cairo). 2014;2014:292545
pubmed: 24949019
Ann Fam Med. 2010 Jan-Feb;8(1):58-63
pubmed: 20065280
Int J Clin Pract. 2009 Apr;63(4):606-12
pubmed: 19222617
Eur Respir J. 2013 Feb;41(2):433-42
pubmed: 23100492
Am J Respir Crit Care Med. 2009 Jul 1;180(1):29-35
pubmed: 19324973
Cochrane Database Syst Rev. 2013 Nov 05;(11):CD000023
pubmed: 24190439
Part Fibre Toxicol. 2015 Jul 04;12:20
pubmed: 26141115
Eur Arch Otorhinolaryngol. 2016 Sep;273(9):2591-7
pubmed: 27126336
Int J Chron Obstruct Pulmon Dis. 2016 Oct 18;11:2573-2583
pubmed: 27799756
Cochrane Database Syst Rev. 2007 Jul 18;(3):CD006394
pubmed: 17636843
JAMA. 2017 Apr 18;317(15):1535-1543
pubmed: 28418482
Ann Fam Med. 2006 Nov-Dec;4(6):494-9
pubmed: 17148626
Sci Rep. 2019 Jan 31;9(1):1015
pubmed: 30705369
Biol Chem. 2010 Nov;391(11):1327-32
pubmed: 20868224
Ann Intern Med. 2016 Mar 15;164(6):425-34
pubmed: 26785402
Oncol Ther. 2018 Jun;6(1):59-72
pubmed: 32700140
Curr Med Res Opin. 2013 Jul;29(7):739-46
pubmed: 23621514
HNO. 2011 May;59(5):480-4
pubmed: 21424132
Protein Pept Lett. 2012 Aug;19(8):791-4
pubmed: 22702895
Biophys Chem. 2010 Aug;150(1-3):37-46
pubmed: 20206435
Drug Res (Stuttg). 2016 Jul;66(7):384-92
pubmed: 27281448
Cochrane Database Syst Rev. 2016 Apr 26;4:CD011995
pubmed: 27115216
Sci Rep. 2016 Aug 16;6:31434
pubmed: 27527336
Skin Pharmacol Physiol. 2014;27(2):57-65
pubmed: 23949258
Int J Clin Pract. 2017 Oct;71(10):
pubmed: 28869700
Cochrane Database Syst Rev. 2013 Jul 31;(7):CD006458
pubmed: 23900970
J Allergy (Cairo). 2014;2014:176597
pubmed: 24982680
BMJ Open. 2014 Oct 27;4(10):e006245
pubmed: 25348424
J Allergy (Cairo). 2014;2014:708458
pubmed: 24822073
J Allergy (Cairo). 2014;2014:273219
pubmed: 24822072
N Engl J Med. 2011 Feb 17;364(7):648-55
pubmed: 21323542
Pain Manag. 2016 Nov;6(6):519-529
pubmed: 27734772
BMC Fam Pract. 2014 Mar 13;15:45
pubmed: 24621446
Biophys Chem. 2012 Jan;160(1):62-8
pubmed: 22014723
Phytomedicine. 2013 May 15;20(7):585-91
pubmed: 23453305
JAMA Intern Med. 2014 Jan;174(1):138-40
pubmed: 24091806
Part Fibre Toxicol. 2012 Dec 10;9:48
pubmed: 23228165
Biophys J. 1985 Mar;47(3):411-4
pubmed: 3978211